FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product
BUFFALO, N.Y., Dec. 23 (Korea Bizwire) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that the U.S. Food and Drug Administration (FDA) has authorized the marketing of the Company’s VLN® King and VLN® Menthol King reduced [...]